maretak bij kanker, Iscador


logo.jpg (7231 bytes)

Google

Deze pagina is verouderd - ontvang onze nieuwtjes per email

 

Maretak bij kanker, Iscador


Doordat ik veel sites bezoek loop ik steeds weer tegen zaken aan die bij mij ook onbekend waren. Het gaat om met name natuurlijke oplossingen voor ziektes zoals kanker. Waarom lees ik dit niet in de media? Heel simpel, de kranten weigeren aandacht te besteden aan dit soort zaken en willen het volk dus dom houden over alternatieven voor reguliere behandelmethodes.

Ik kan echt kwaad worden om dit soort zelfcensuur, de journalisten bepalen dus wat goed voor ons is om te weten. De heksenjacht van de anti kwakzalver club wordt medegesteund door volgelingen onder journalisten dus bent u aangewezen op alternatieve tijdschriften en internet want de media vindt dit soort zaken blijkbaar niet interessant en loopt liever de introduktie feestjes af van nieuwe medicijnen. Maar goed, ik kan die wereld niet veranderen en er zullen hopelijk journalisten opstaan die echt onderzoek willen gaan doen naar oplossingen als Iscador, Ukrain etc etc.

Ondertussen ga ik door op kleinere schaal en geef u wel de informatie over zowel reguliere als alternatieve mogelijkheden. Laat u nooit afbluffen door vaktermen, verbreedt je kennis zodat je betere keuzes kunt maken en alle voordelen en nadelen van behandelmethodes kunt afwegen.

Nederland loopt flink achter op andere landen waar wel serieus naar alternatieve methodes wordt gekeken. In het calvinistische Nederland is de patiënt helaas nog aangewezen op een kleine groep artsen die breder willen kijken en de oorzaak van de ziekte willen aanpakken en niet alleen de symptomen.

Men heeft via de rechter geprobeerd het middel Iscador van de markt te krijgen maar tot in hoger beroep heeft de rechter de minister in het ongelijk gesteld en mag het dus worden voorgeschreven door antroposofische artsen.

Ron


Werking Iscador

Uit wetenschappelijk onderzoek (*) komen aanwijzingen dat Iscador de volgende werkingen heeft:

  • Het middel bevat stoffen die de celdeling van tumoren kunnen afremmen of deze cellen doen sterven. (9-11a)
  • Het activeert het immuunsysteem, waardoor onze lichamelijke afweer toeneemt. (1, 13-15, 16, 17)
  • Het doet de zelfregulatie toenemen. Hiermee wordt bedoeld: het vermogen om het leven meer in eigen hand te nemen. Het gevolg hiervan is onder andere een verhoogd gevoel van welbevinden en meer zekerheid. (1-7, 12, 12a)
  • Iscador stimuleert de aanpak van pijn onderdrukkende stoffen in het eigen lichaam en kan daardoor pijnstillend werken. (1-3, 6, 8)
  • Indien tijdig gestart (vóór de operatie of tijdens de bestraling en/of de chemotherapie) leidt de Iscador-behandeling tot een beter en sneller herstel van deze ingrepen. De ontwikkeling van recidiven en metastasen wordt geremd en de bijwerkingen verminderen. (9-11a, 18)

Meer info: http://www.weleda.nl/d_geneesmiddelen/kanker_en_iscador.htm

(*) Studies

1 Hajto et al, Deutsche Onkologie 1991/23/1, p. 1-6.

2 Wagner, Prakische Prüfungsmethoden zur Beurteilung der Misteltherapie, Urachhaus, Stuttgart 1994.

3 Wagner, Iscador M/Qu spezial, Urachhaus Stuttgart 2001.

4 Grossarth-Maticek et al, Alternative Therapies 2001/7/3, p. 57-78

5 Borelli, La Medicina Biologica 1999, p. 27-30.

6 Hassauer et al, Onkologie 2 1979/1, p. 28-36.

7 U. Dold et al, Krebszusatztherapie beim nicht-kleinzelligen Bronchial- karzinom, Thieme Verlag, Stuttgart 1991.

8 Leroi, Ärztliche Praxis 1983/35/19, p. 482-87.

9 Ribéreau-Gayon et al, Experientia 1986/42, p. 594-99.

10 Kuttan et al, Cancer Letters 1998/41, p. 307-14.

11 Kuttan et al, J. Ethnopharmacology 1990/29, p. 35-41.

11a J. Nienhaus et al, Elemente der Naturwissenschaft 1970/13/2, p. 45-54.

12 Hajto et al, Clinical Tri J. 1986/23/6, p. 345-58.

12a Wagner, Immunologie und Krebskrankheit, Urachhaus, Stuttgart 1993.

13 Chernyshov et al, Complementary Therapeutic Medecine 1997/5, p. 14-16.

14 E. M. Lukyanova et al, Forschung Komplementärmedizin 1994/1/2, p. 58-70.

15 T. Hajto, Oncology 1986/43 (suppl. 1), p. 51-65.

16 M. Stoss et al, Arzneimittel-Forschung/Drug. Research 1999/49/4, p. 366-73.

17 R. W. Gorter et al, Am. J. Therapeutics 1998/5/3, p. 18-1-7.

18 P.R. Bock, J. Hanisch, J. Hoffmann, R.E. Dierdorf, M. Werner, Th. Schürholz en B. Schneider, Wirksamkeit und Unbedenk- lichkeit des standardisierten Mistelextraktes Iscador® in der postoperatieven Therapie von Patienten mit primärem Mammakarzinom: multizentrische, kontrollierte, retrolektive Kohortenstudie, durchgeführt entsprechend den GEP-Richtlinien; Abstract.

Links


Studies naar Iscador


Bron: Altern Ther Health Med. 2001 May-Jun;7(3):57-66, 68-72, 74-6 passim.

Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.

Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R.

Institute for Preventive Medicine, European Center for Peace and Development, United Nations, Heidelberg, Germany.

CONTEXT: In anthroposophical medicine, total extracts of Viscum album (mistletoe) have been developed to treat cancer patients. The oldest such product is Iscador. Although Iscador is regarded as a complementary cancer therapy, it is the most commonly used oncological drug in Germany.

CONCLUSION: Iscador treatment can achieve a clinically relevant prolongation of survival time of cancer patients and appears to stimulate self-regulation.

Bron: Altern Ther Health Med. 2001 May-Jun;7(3):57-66, 68-72, 74-6 passim.


Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma.

Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland

Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B.

Institut fur Angewandte Gesundheitsforschung, IFAG Basel AG, Basel, Schweiz.

OBJECTIVES: The purpose of the study was to evaluate the therapeutic efficacy and safety of long-term complementary therapy in primary, non-metastatic mammary carcinoma patients in UICC stage I-III with a standardized European mistletoe extract (Viscum album L., Iscador, "mistletoe extract") given in addition to conventional adjuvant oncologic therapy (i.e. chemo-, radio-, and hormonal therapy; "conventional therapy").

CONCLUSIONS: The results of the present study confirmed the safety of the complementary therapy of patients with primary, non-metastatic mammary carcinoma with a standardized mistletoe extract and showed considerably fewer ADRs attributed to concurrent conventional therapy, as well as reduced disease and treatment-associated symptoms, and suggested a prolonged overall survival in the mistletoe extract group as compared with controls.

Bron: Arzneimittelforschung. 2004;54(8):456-66


Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects.

Huber R, Rostock M, Goedl R, Ludtke R, Urech K, Buck S, Klein R.

Center for Complementary Medicine, University Hospital Freiburg, Breisacher Str. 60, D-79106 Freiburg, Germany. rhuber@medizin.ukl.uni-freiburg.de

OBJECTIVE: Various immunological effects have been reported during application of mistletoe preparations. Because these data are heterogeneous, we performed a placebo controlled study to investigate (1) effects on peripheral granulocyte and eosinophil counts, (2) related cytokine levels and (3) whether effects are related to mistletoe lectin (ML).

METHODS: 43 volunteers were randomized to receive the mistletoe plant extract Iscador Quercus spezial (IQ), purified ML, IQ which was depleted from ML, or placebo subcutaneously twice per week for 8 weeks. Weekly, differential blood count and every four weeks spontaneous and IQ- and ML-induced cytokine production by peripheral blood mononuclear cells (PBMC) were analyzed.

RESULTS: Leukocyte-, granulocyte-, and eosinophil counts were significantly higher during treatment in the IQ- and ML-groups than in the placebo group. Furthermore, a significant increase of antigen-induced production of GM-CSF, IL-5 and IFNgamma by PBMC was observed in the IQ- and ML-group but not in the groups receiving ML-depleted IQ or placebo. Severe side effects did not occur in any of the subjects.

CONCLUSIONS: Treatment with IQ or ML stimulates the production of GM-CSF, IL-5 and IFNgamma by PBMC, and this is accompanied by an increase of eosinophil- and granulocyte-counts. These observations may, therefore, open rational therapeutic indications for mistletoe extracts.

Bron: Eur J Med Res. 2005 Oct 18;10(10):411-8


Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".

Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B.

Institute for Applied Medical Research, IFAG Basel AG, Hohenrainweg 105, CH-4444 Rumlingen, Switzerland. paulrbock@aol.com

The randomized controlled clinical trial (RCT) is accepted as the "golden standard" for the evaluation of efficacy and safety of new drugs. In contrast, to demonstrate efficacy and safety of drugs with "well-established use" that have been on the European Community market for long time, observational comparative epidemiological studies can be used according to the European drug regulation directive. However, because comparative epidemiological cohort studies can share some risk of bias with other nonrandomized observational study designs, there is a need for an approach that could effectively reduce the bias risk in this type of studies.

STUDY OBJECTIVES: The purpose of the study was to evaluate the therapeutic efficacy and safety of a long-term complementary therapy of primary, non-metastatic breast carcinoma patients treated with standardized European mistletoe extract Iscador("mistletoe") in addition to the conventional adjuvant oncologic therapy, and compared to the control group treated with the conventional therapy alone.

CONCLUSIONS: Complementary therapy of patients with primary, non-metastatic breast carcinoma with the mistletoe extract Iscador was safe and in comparison to the control group within the same study cohort showed considerably fewer ADRs attributed to concurrent conventional therapy, reduced disease symptoms, and suggested a significant improvement of survival. Despite some methodical limitations that require careful study planning and conduction as well as critical interpretation, the applied study design seems suitable to evaluate the efficacy and safety of drugs with "well-established use", particularly in oncology. Copyright 2004 S. Karger GmbH, Freiburg

Bron: Forsch Komplementarmed Klass Naturheilkd. 2004 Aug;11 Suppl 1:23-9.


Wil je meer onderzoeken bekijken? Ga dan naar deze site en type Iscador in de zoekbalk

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Pager&DB=pubmed

Zet de optie display op abstract zodat je snel de resultaten kunt lezen.

 

 

 


 


View My Stats